According to the American Cancer Society, prostate cancer is the second-leading cause of cancer-related death in males in the United States, behind only lung cancer. Around 1 out of every 8 men will be diagnosed with prostate cancer at some point in their lives. In most cases, it is treatable, yet there are some cases where all known therapies are met with resistance and things take a turn for the worse. However, a new study involving mouse models revealed that a precursor to vitamin K can potentially slow prostate cancer growth.
Groundbreaking Study on Vitamin K and Cancer
researchers in a lab
Credit: Pexels
A recent discovery at Cold Spring Harbor Laboratory potentially offers a novel solution to the prostate cancer issue. Professor Lloyd Trotman and his team have discovered that the pro-oxidant supplement menadione reduces the development of prostate cancer in studies involving mice. Menadione is found in leafy greens and is a precursor to vitamin K. While this study itself is new, it is the result of another study that took place at the beginning of this century.
ADVERTISEMENT
